



# Genetic Signatures

2015 AGM Presentation

# Disclaimer

This presentation was prepared by Genetic Signatures Limited known as “Genetic Signatures“, (“GSS” or “the Company”), in order to discuss its business with various interested parties. This presentation in its entirety has been released to the market via the Australian Securities Exchange Limited (“ASX”).

This presentation contains statements that involve estimates, risks and uncertainties. Although the Company believes these statements to be reasonable at this time, Genetic Signatures can give no guarantee that the expectations reflected in these statements will prove to be accurate. Actual results could differ materially from those expected for any of a multitude of risks including, but not limited to, those inherent in regulatory or market environments or more generally. In preparing this presentation, the Company has relied upon and assumed, without independent verification, the accuracy and completeness of all information available from public sources, or which was otherwise reviewed by it.

The presentation is proprietary to Genetic Signatures and may not be disclosed to any third party or used for any other purpose without the prior written consent of the Company.

This document does not constitute an offer, solicitation or recommendation in relation to the subscription, purchase or sale of securities in any jurisdiction and does not and will not form part of any securities subscription, purchase or sale contract.

# Transforming Molecular Diagnostics


Genetic Signatures is a molecular diagnostics (MDx) company operating in the global IVD (*in vitro* diagnostics) industry with new technology in infection control.

Our primary focus is the **development and supply of world leading diagnostic solutions** to hospitals and pathology laboratories globally for rapid detection and treatment of infectious diseases.



# Company Overview

- Genetic Signatures provides diagnostic solutions for rapid pathogen detection
- Proprietary technology driving product development for pathology and hospital customers globally in multiple markets, with IP protection to 2031
- Products already available in Australia and now launching into large global markets, worth **US\$1.11 billion** in 2012 growing to **US\$1.77 billion in 2017**
- Experienced management team and board with track record in global molecular diagnostics industry



# Corporate Summary

Capital Structure	
ASX Code	GSS
Shares on Issue	72.9m
Market Capitalisation	\$38m
Share Price (at market close 6 November, 2015)	\$0.525
Cash at 30 September 2015	\$5.47m

Directors & Chief Executive	
Nick Samaras	Non-Executive Chairman
John Melki	Director & CEO
Mike Aicher	Executive Director - US
Phillip Isaacs	Non-Executive Director
Tony Radford – appointed 15 <sup>th</sup> September 2015	Non-Executive Director

# Board and Management

## **Nick Samaras - Non-Executive Chairman**

*BSc (Hons), PhD, MBA, FAIM, FAICD*

- More than 25 years' experience in the global life sciences industry, senior executive roles with Applied Biosystems (now part of Thermo Fisher) and Perkin Elmer
- NHMRC Research Committee member 2006-12, Adjunct Professor La Trobe University, Founder of consulting firm Australis Biosciences and Director of the AGRF and MuriGen Therapeutics

## **John Melki - Managing Director & CEO**

*BSc (Hons), PhD*

- Chief Executive Officer since 2011, joined GSS in 2003
- Led the commercialisation of two research products worldwide and five diagnostic products in Australia and Europe

## **Mike Aicher - Executive Director – US Operations**

*BSc, MBA*

- More than 30 years of industry experience
- Previously CEO and founder of National Genetics Institute (NGI), acquired by Laboratory Corporation of America, Inc (Labcorp) in 2000
- Responsible for LabCorp's Esoteric Businesses in the U.S. which generated more than \$1 billion in annual revenue
- Director on boards of Kinetic Diagnostics Inc and Omicia, Inc

# Board and Management

## **Tony Radford - Non-Executive Director**

*BSc (Hons), PhD*

- A member of the CSIRO team that invented the QuantiFERON method for Cellular Immune based diagnostics
- Co-founded the diagnostic company Cellestis Limited which listed on the ASX in 2001
- Former CEO of Cellestis from founding until its acquisition by QIAGEN NV in 2011 for approximately \$400 million
- Established offices and operations in the USA, Europe and Japan, Cellestis developed QuantiFERON –TB Gold, the worldwide benchmark for the diagnosis of tuberculosis infection
- Previous Head of Development (2000) at AMRAD (now part of CSL) in pharmaceutical research

## **Phillip Isaacs - Non-Executive Director**

*MSc, JP*

- More than 30 years of industry experience
- Previously Managing Director, Asia Pacific, for Beckman Instruments
- Vice President of the Asia Pacific Cytoc Corporation which developed and sells the ThinPrep Pap
- Founding Chairman of the Australian Proteome Analysis Facility (APAF) in Sydney

# 2015 Highlights

## Financial Growth

- Completed oversubscribed Initial Public Offering (IPO) to raise \$7.5 million and list on the Australian Securities Exchange (ASX)
- Achieved greater than \$1 million in annual sales revenue for the first time in the history of the Company - **revenue for FY15 up 52% to \$1,043,269**
- Diagnostic kit sales revenue increase of 65% on previous year
- **September quarter diagnostic kit sales \$442,000 up 44.3% on previous quarter and 138% increase on corresponding 2014 quarter**
- Australian hospitals and laboratories performed GSS *EasyScreen™* tests 55,000 times in FY15
- First molecular diagnostic kits sales to a major national pathology provider
- **First molecular diagnostic kit sales into Europe achieved**
- Government Research Grant received \$968,000
- Cash at September 30, \$5,472,000

# Genetic Signatures

## Transforming Global Molecular Diagnostics




# Technology - 3Base™

Platform technology converts original 4-base microbial genome to 3-base, thereby reducing complexity in molecular testing. Applicable in testing for infectious diseases and chronic diseases including cancers

## Overview of 3base™

Basic Technical functionality: Moving from 4base to 3base™



# Technology - 3Base™

- 3Base™ improves subtype similarity and reduces variation, allowing easier PCR design
- e.g, a 10 digit number comprised of the numbers 1,2,3 and 4 has **1,048,576 combinations**
- a 10 digit number comprised of the numbers 1,2 and 3 has **59,049 combinations**

e.g. Non-Converted Influenza Sequences		3base™ Converted Influenza Sequences	
Influenza A virus H5N1	TGTGTGTCCA GGGATAATTG	Influenza A virus H5N1	TGTGTGTITA GGGATAATTG
Influenza A virus H7N3	TGTATATGTA GGGACAATTG	Influenza A virus H7N3	TGTATATGTA GGGATAATTG
Influenza A virus H5N8	TGTGTTTGTA GAGACAATTG	Influenza A virus H5N8	TGTGTTTGTA GAGATAATTG
Influenza A virus H5N3	TGTATATGTA GGGACAATTG	Influenza A virus H5N3	TGTATATGTA GGGATAATTG
Influenza A virus H5N2	TGTGTTTGCA GAGATAATTG	Influenza A virus H5N2	TGTGTTTGTA GAGATAATTG
Influenza A virus H6N6	TGCATTTGCA GGGACAATTG	Influenza A virus H6N6	TGTATTTGTA GGGATAATTG
Influenza A virus H2N9	TCCAATTGCA GGGATAATTG	Influenza A virus H2N9	TTTATTTGTA GGGATAATTG
Influenza A virus H6N5	TGCGTTTGCC GAGATAATTG	Influenza A virus H6N5	TGTGTTTGT GAGATAATTG
<b>Consensus</b>	<b>TSYRYDTSYM GRGAYAAVTG</b>	<b>Consensus</b>	<b>TKTRTDTKTW GRGATAATTG</b>
	<b>768 Possible combinations</b>		<b>24 Possible combinations</b>
	<b>55% Homology</b>		<b>80% Homology</b>

- Sufficient information is retained for genotyping equivalent to native (4Base) genomic assays
- No loss of clinical specificity is observed by this base conversion
- e.g. HPV clinical trials showed superior performance vs. Digene HC2 assay in reducing false positives
- 3Base™ delivers greater Sensitivity and Specificity

# Technology - 3Base™

*A transformational MDx technology enabling customers to identify a wider array of patient infections*

- Genetic Signatures' 3Base™ platform is a proprietary molecular technique which changes naturally occurring DNA and RNA sequences to reduce sequence variation between subtypes
- Patent-protected chemical transformation of DNA and RNA sequences to reduce genetic code complexity
- Process can enhance detection of multiplexed assays where multiple targets are detected in the one tube
- Achieved by allowing a simpler design of molecular assays for the simultaneous detection of multiple targets

# Targeting Critical Health

- Gastroenteritis is a major widespread clinical problem (16.8 million cases per annum in Australia alone) **resulting in 250,000 visits to hospital emergency departments, 15,000 hospitalisations and 80 deaths**)
- Genetic Signatures' gastroenteritis testing offers faster and more reliable diagnosis for better treatment
- Viral Respiratory Infections **kill 3.9 million people per year - one of the top five causes of mortality worldwide**
- Genetic Signatures' product pipeline includes tests for bacterial respiratory infections, MRSA (Golden Staph), meningitis, TB and STI's. Other tests being evaluated, eg Ebola



## *EasyScreen*<sup>™</sup> Testing Kits

- GSS' suite of *EasyScreen*<sup>™</sup> products are used by major hospitals in Australia for detection of infectious diseases – **55,000 tests were sold and used in FY15**
- Products work with existing customer systems to deliver a wider array of highly **specific results in 4-5 hours that would have traditionally taken 4-5 days**
- *EasyScreen*<sup>™</sup> technology works on equipment found in any diagnostic laboratory
- Enteric Pathogen Detection Kit detects up to **22 gastroenteritis pathogens, including viral, bacterial and protozoan agents**
- Respiratory Virus Detection Kit detects up to 15 of the most common respiratory viral infections

# Case Study:

## St Vincent's Hospital Evaluation Study

### - *EasyScreen*<sup>™</sup> vs. Traditional Methods


#### METHODS:

- Primary focus of study was to assess the clinical utility of *EasyScreen*<sup>™</sup> in detecting infectious agents in 221 patient samples as compared to traditional methods of culture, microscopy and antibody based tests
- Identified 44 infections that existing testing would have missed**
- Missed infections within the hospital environment can have substantial downstream consequences such as the closing down of wards (e.g. **Norovirus group II**)


Pathogen	Conventional Methods*	<i>EasyScreen</i> <sup>™</sup>
Campylobacter	7	9
Salmonella	8	9
Shigella	5	6
C. Difficile	3	7
Yersinia	-	1
Cryptosporidium	-	1
Giardia	9	12
Dientamoeba fragalis	4	20
Blastocystis hominis	16	21
Entamoeba histolytica	1	1
Norovirus group 2	-	7
Adenovirus	-	1
Adenovirus 40/41	-	1
Sapovirus	-	1
<b>Total</b>	<b>53</b>	<b>97</b>

**“I find that the fast turnaround time and the number of targets tested in the *EasyScreen*<sup>™</sup> assays allow me to more rapidly identify highly infectious agents, potentially stopping the spread to other healthy individuals and thereby saving the health system money.”**

**- Dr Damien Stark**



# EasyScreen™ Product Development Pathway




Each product goes through extensive development and beta testing and adheres to rigorous quality management systems & regulatory approach.

- ISO9001 and ISO13485 certified
- Already approved by Australian and European regulators

# Competitive Advantage

- GSS is unique in supplying products that screen over 20 pathogens, including RNA and DNA viruses, in a probe based real-time format
- Uses latest technology compatible with existing equipment (open platform)
- Ease of use and automation
- Rapid time to result (<5hrs)
- High Volume laboratories accommodated
- Separate endogenous extraction and inhibition controls
- Viral, bacterial and protozoan coverage
- Cost effective kits supply
- Ongoing global support



# Global Growth Strategy



# 2015 Operational Highlights

## Global Market Reach Expansion

- US subsidiary, Genetic Signatures US Ltd incorporated and its US team expanded
- Established first European sales channel partnerships with distributors for the regions of Italy and Israel

## Product Range Expansion

- Moved into new state of the art premises, allowing for increased product development
- Completed first domestic customer site installation of *EasyScreen™* Respiratory Virus Detection Kit for beta-testing
- First sales of *EasyScreen™* Respiratory Virus Detection Kit

## Commercialisation Progress - Australia

- Currently in market with major hospital and pathology group customers
- Australian hospitals and laboratories performed GSS EasyScreen™ tests ~55,000 times in FY15
- Testing for 22 causes of gastroenteritis
- Testing for 15 causes of viral respiratory disease
- Next new product in beta testing with customer
- Dr Tony Radford joined Board of Directors

## Commercialisation Progress - Europe

- Established operations in 2013
- Signed Italian distributor and testing with large pathology laboratories, recurrent revenues commencing
- Signed Israeli distributor agreement
- Increased European sales channel partnership network by signing distribution agreements with partners for the regions of Poland and Ireland
- In discussions with distributors in other jurisdictions



# Commercialisation Progress - United States

- Established operations in 2014 with appointment of key personnel
- In FY15 GSS achieved first regulatory step towards full product suite commercialisation in the US with receipt of a United States Food and Drug Administration (FDA) listing for a clinical sample concentrator. **The FDA listing means that the Company can legally sell its *EasyScreen™* Sample Processing Kit in the US**
- Appointment of Pat Noland, to head up Commercial Operations in September
- **University of California Los Angeles to collaborate with Genetic Signatures on transformative molecular platform technology**



# Immense US Market Potential

- US has 5,686 registered hospitals
  - Over 900,000 staffed beds
  - Over 35 million admissions
- *3Base™* Technology offers unique advantages for the US Market
  - High numbers of pathogens detected delivers desirable patient outcomes
  - Assays available for *C. difficile*, which the CDC cites as an “urgent threat”
- Independent and commercial labs represent approximately 50% of the US laboratory testing market

# US Market Trends

- Centers for Disease Control and Prevention (CDC) estimates that annually, at **least two million illnesses and 23,000 deaths are caused by antibiotic-resistant bacteria in the United States alone**
- The Infectious Disease Society of America produced a policy paper “Better Tests, Better Care: Improved Diagnostics” in which the society advocates for molecular testing development and adoption to improve patient care and distinguish between bacterial and viral pathogens
- Laboratories are **bracing for implementation of the Preserve Access to Medicare Act which will likely lower reimbursement** beginning in 2017
  - Laboratories will consider new methods for diagnosis
    - Adopt molecular technology to speed broad diagnosis
  - Laboratories will seek to lower their operating expense
    - **Favour high throughput to improve efficiency**
    - **Favour open platform systems to lower capital expense requirement**

# US Market Expansion Approach

- Discussions underway with Key Opinion Leaders to research Genetic Signatures' technology
  - Patient outcome studies – define superior patient care through implementation of broad pathogen screening protocols
  - Head-to-Head comparison between *3Base™* assays and traditional methods and available molecular alternatives
  - Overall cost of care economic benefit of *3Base™* technology implementation
- Engaged with leading US commercial laboratories and hospital systems to introduce *3Base™* technology
  - Evaluate *3Base™* versus traditional 4 base molecular performance
  - Evaluate widespread adoption of molecular methods versus traditional methods

# Summary

- *EasyScreen™* Respiratory & Enteric Pathogen Detection Kits provide **faster & more accurate screening** for viral, bacterial and protozoan pathogens – **tests are processed in hours instead of days**, with fewer false positives and negatives
- The 3Base™ platform and products are protected by a patent portfolio - **protecting the 3Base™ technology platform until 2031**
- Products already available in Australia with GSS having launched into global markets worth **US\$1.11 billion** in 2012 growing to **US\$1.77 billion in 2017**
- **Established operations in key global markets** of Europe and the US over the past year
- **Experienced management team and board** with track record in global molecular diagnostics industry

A group of belugas swimming in blue water. The image is monochromatic with a blue tint. A dark blue semi-transparent box is overlaid in the center, containing contact information.

**Contact:**

**John Melki**  
**Chief Executive Officer**  
[john@geneticsignatures.com](mailto:john@geneticsignatures.com)

[www.geneticsignatures.com](http://www.geneticsignatures.com)